Healthcare entity
FDA is the most frequent co-covered peer, appearing in 2 of the 4 tracked stories. The 17-day window averages about 1.6 stories each week. Their average consequence score of 6.3 runs above the beat's 5.8 for that window. Source depth averages 3 original sources per story, versus 3.3 across the same-window beat baseline.
Last mentioned: Aug 10, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
FDA is the most frequent co-covered peer, appearing in 2 of the 4 tracked stories. The 17-day window averages about 1.6 stories each week. Their average consequence score of 6.3 runs above the beat's 5.8 for that window. Source depth averages 3 original sources per story, versus 3.3 across the same-window beat baseline. The clearest coverage concentration is market-trends: 2 of 4 stories, with the rest divided among 1 other category. We currently track 4 Healthcare stories that mention GLP-1, published between February 24, 2026 and March 12, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 344 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GLP-1. Shared-story counts are live from our verified record — not editorial picks.
Payer Agreement Shift
New payer contracts take effect, shifting GTN expectations to the high 30% range for the fiscal year.
Q4 Milestone
Patient count surpasses 36,000 and quarterly revenue exceeds $320 million.
GLP-1 Strategic Acquisition
Madrigal makes a $120 million upfront payment for an oral GLP-1 asset to expand its metabolic pipeline.
Rezdiffra Full-Year Launch
Madrigal begins its first full year of commercial sales for the first-ever approved MASH treatment.
The FDA has issued a formal warning letter to Novo Nordisk for failing to properly report serious adverse events, including deaths and strokes, related to its GLP-1 medications. This regulatory escalation coincides with a significant market valuation decline and intensifying competition from compounding pharmacies.
Source: gulfcoastnewsnow.com · koco.com
Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in its weight-loss business strategy. This move follows mounting pressure from pharmaceutical manufacturers and highlights the tightening regulatory environment for telehealth platforms leveraging drug shortages.
Agilent Technologies reported a resilient Q1 2026 with $1.8 billion in revenue, driven by a 7% growth in the pharma sector despite significant headwinds in academic and government funding. While the company faced a 100-basis-point gross margin compression due to rising tariffs and weather disruptions, strong performance in the Agilent CrossLab Group suggests a shift toward service-oriented recurring revenue.
Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)
Madrigal Pharmaceuticals reported a transformative Q4 2025, with Rezdiffra net sales reaching $321.1 million and a patient base exceeding 36,000. The company is aggressively expanding its metabolic pipeline, integrating GLP-1 and siRNA technologies to solidify its leadership in the MASH market.
Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)
GLP-1 is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
